Eyenovia Executives
| EYENDelisted Stock | USD 14.36 1.94 11.90% |
Eyenovia employs about 13 people. The company is managed by 9 executives with a total tenure of roughly 31 years, averaging almost 3.0 years of service per executive, having 1.44 employees per reported executive. Analysis of Eyenovia's management performance can provide insight into the firm performance.
Eyenovia |
Eyenovia Management Team Effectiveness
The company has return on total asset (ROA) of (1.1774) % which means that it has lost $1.1774 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.8803) %, meaning that it created substantial loss on money invested by shareholders. Eyenovia's management efficiency ratios could be used to measure how well Eyenovia manages its routine affairs as well as how well it operates its assets and liabilities.The market capitalization of Eyenovia is $80.75 Million. Roughly 86.19 percent of Eyenovia outstanding shares are held by general public with 0.42 (percent) owned by insiders and only 13.39 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Some institutional investors establish a significant position in stocks such as Eyenovia in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Eyenovia, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Eyenovia Workforce Comparison
Eyenovia is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 613. Eyenovia holds roughly 13.0 in number of employees claiming about 2.12% of equities under Health Care industry.
Eyenovia Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eyenovia insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eyenovia's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Eyenovia insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mather Charles E Iv over six months ago Acquisition by Mather Charles E Iv of 61481 shares of Eyenovia subject to Rule 16b-3 | ||
Palanki Ram over six months ago Acquisition by Palanki Ram of 3000 shares of Eyenovia subject to Rule 16b-3 | ||
Geltzeiler Michael S over six months ago Acquisition by Geltzeiler Michael S of 5000 shares of Eyenovia subject to Rule 16b-3 | ||
Michael Rowe over six months ago Acquisition by Michael Rowe of 4890 shares of Eyenovia at 1.36 subject to Rule 16b-3 | ||
Jacobson Rachel over six months ago Acquisition by Jacobson Rachel of 24691 shares of Eyenovia at 2.32 subject to Rule 16b-3 | ||
Michael Rowe over six months ago Acquisition by Michael Rowe of 27071 shares of Eyenovia at 0.52 subject to Rule 16b-3 | ||
Michael Rowe over a year ago Acquisition by Michael Rowe of 4890 shares of Eyenovia at 1.36 subject to Rule 16b-3 | ||
Mather Charles E Iv over a year ago Acquisition by Mather Charles E Iv of 3000 shares of Eyenovia at 2.4899 subject to Rule 16b-3 |
Eyenovia Notable Stakeholders
An Eyenovia stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Eyenovia often face trade-offs trying to please all of them. Eyenovia's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Eyenovia's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Rowe | President CEO | Profile | |
| John CPA | CFO Secretary | Profile | |
| Andrew Jones | Chief Officer | Profile | |
| Bren Kern | VP Operations | Profile | |
| Enrico Brambilla | Senior RD | Profile | |
| Tony Cardinale | Vice Sales | Profile | |
| Norbert Lowe | Senior Operations | Profile | |
| Alexander Lobo | Investor Contact | Profile | |
| MD MPH | President, CoFounder | Profile |
About Eyenovia Management Performance
The success or failure of an entity such as Eyenovia often depends on how effective the management is. Eyenovia management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Eyenovia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Eyenovia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York. Eyenovia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 43 people.
Eyenovia Workforce Analysis
Traditionally, organizations such as Eyenovia use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Eyenovia within its industry.Eyenovia Manpower Efficiency
Return on Eyenovia Manpower
| Revenue Per Employee | 4.4K | |
| Revenue Per Executive | 6.4K | |
| Net Loss Per Employee | 3.8M | |
| Net Loss Per Executive | 5.5M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Eyenovia Stock
If you are still planning to invest in Eyenovia check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eyenovia's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |